Breaking News Instant updates and real-time market news.

LOXO

Loxo Oncology

$168.39

29.44 (21.19%)

, JNCE

Jounce Therapeutics

$11.96

-5.705 (-32.30%)

10:56
05/17/18
05/17
10:56
05/17/18
10:56

Loxo gains, Jounce plunges after cancer meeting abstracts released

Shares of Loxo Oncology (LOXO) jumped in morning trading after the biotech company released data in abstracts in anticipation of the 2018 American Society of Clinical Oncology Annual Meeting that is being held June 1-5 in Chicago. The data showed that its experimental LOXO-292 cancer drug shrunk tumors in nearly 70% of patients regardless of where their cancer originated. Meanwhile, Jounce Therapeutics (JNCE) said it is planning to unveil data from a trial evaluating JTX-2011 monotherapy and in combination with Bristol-Myers' (BMY) nivolumab, which is marketed as Opdivo. WINNER: According to preliminary data from an abstract released on Wednesday, Loxo Oncology's LOXO-292 drug, a highly selective RET inhibitor, shrunk tumors in almost 70% of patients regardless of cancer origination. LOXO-292 is an oral and selective investigational new drug in clinical development for the treatment of patients with cancers that harbor abnormalities in the rearranged during transfection kinase. According to Loxo, the drug was well-tolerated and had "marked antitumor activity in patients with RET-altered cancers, including those with resistance to prior treatments." Blueprint Medicines (BPMC), which is developing a drug that rivals LOXO-292, plunged this morning after certain of Loxo's ORR figures were said by analysts to have topped Blueprint's previously released figures from a past conference. Blueprint will present two abstracts at ASCO supporting plans for rapid development of avapritinib, a selective KIT and PDGFRa inhibitor, in patients with gastrointestinal stromal tumors and systemic mastocytosis. LOSERS: Meanwhile, an abstract was released for Jounce Therapeutics' ICONIC trial, which is comparing JTX-2011 on its own and in combination with Bristol-Myers Squibb's Opdivo in ICOS-positive tumors. The abstract published online reflects data as of January 27 and updated results will be presented on June 2. Jounce said it has met its target enrollment for the Phase 1/2 trial in combination cohorts across gastric cancer, triple negative breast cancer, head and neck squamous cell cancer and nonsmall cell lung cancer. Elizabeth Trehu, Jounce's chief medical officer, commented that "the preliminary data from patients across multiple solid tumor types enrolled in the ICONIC trial show that JTX-2011 is well-tolerated alone and in combination with nivolumab and has demonstrated evidence of biologic activity and tumor reductions in heavily pre-treated patients who have failed all available therapies." In addition, she added that a potential surrogate biomarker of response has been identified that "may help to guide JTX-2011 development." Another ASCO loser this morning is Nektar Therapeutics (NKTR), which released abstracts that included updated data from the Phase 1/2 PIVOT study evaluating NKTR-214 plus Bristol-Myers' Opdivo in patients with advanced solid tumors, which showed an overall response rate of 52% in melanoma and disease control rate of 78%. ANALYST COMMENTARY: Stifel analyst Stephen Willey raised his price target on Loxo Oncology to $190 from $145, telling investors that the LOXO-292 data should further distance the candidate from other competitive RET inhibitors. Willey noted that the ORR of 52% reported for the 46 evaluable patients harboring RET-altered tumors tops the 46% ORR previously-reported for competitor Blueprint Medicines' BLU-667 at AACR. Jounce was downgraded to Market Perform from Outperform at Wells Fargo by analyst Jim Birchenough following the "underwhelming" JTX-2011 data, saying that the results were "not competitive with other investigational drugs." JPMorgan analyst Jessica Fye said Nektar's NKTR-214 update was not definitive as it relates to the ultimate profile for the product, telling investors that management emphasized in advance that follow up would be limited for the new patients in the abstract, and this was "abundantly evident" with 22 of the 30 Phase II patients having had only one scan. While the limited follow up in the abstract was well-telegraphed, Nektar shares trading modestly lower today would not be surprising, Fye wrote. PRICE ACTION: In morning trading, Loxo Oncology is up over 21% to $169.36, while Jounce Therapeutics is down 32% to $12.06. Blueprint Medicines is lower by about 8% and Nektar Therapeutics is down 8.5%.

LOXO

Loxo Oncology

$168.39

29.44 (21.19%)

JNCE

Jounce Therapeutics

$11.96

-5.705 (-32.30%)

BPMC

Blueprint Medicines

$78.20

-7.92 (-9.20%)

NKTR

Nektar

$77.14

-8.65 (-10.08%)

BMY

Bristol-Myers

$52.54

0.32 (0.61%)

  • 21

    May

  • 21

    May

  • 01

    Jun

  • 12

    Jun

  • 10

    Jul

LOXO Loxo Oncology
$168.39

29.44 (21.19%)

05/17/18
STFL
05/17/18
NO CHANGE
Target $190
STFL
Buy
Loxo Oncology price target raised to $190 after ASCO abstracts at Stifel
Stifel analyst Stephen Willey said he believes the preliminary efficacy data on Loxo Oncology's (LOXO) LOXO-292 that was reported in abstracts released last night in anticipation of the ASCO meeting should further distance the candidate from other competitive RET inhibitors. The overall response rate, or ORR, of 52% reported for the 46 evaluable patients harboring RET-altered tumors tops the 46% ORR previously-reported for competitor Blueprint Medicines' (BPMC) BLU-667 at AACR, noted Willey. The analyst, who also thinks the disclosure of this data increases visibility for potential strategic buyers who have historically shown a "willingness to pay top-dollar for long-duration targeted oncology agents," increased his price target on Loxo to $190 from $145 and keeps a Buy rating on the shares.
04/16/18
04/16/18
UPGRADE
Target $170

Overweight
Loxo Oncology upgraded to Overweight after competitor data at Morgan Stanley
As previously reported, Morgan Stanley analyst Matthew Harrison upgraded Loxo Oncology (LOXO) to Overweight from Equal Weight after competitor Blueprint Medicines (BPMC) provided initial data at the AACR meeting on its RET inhibitor BLU-667 that he believes was at the lower-end of Loxo investors' expectations from a competition standpoint. He now believes Loxo has an opportunity to demonstrate differentiation on both efficacy and safety for LOXO-292 versus BLU-667 when updated data are presented at the ASCO meeting in June. Harrison, who sees the most opportunity for LOXO-292 being a better adverse effect profile, raised his price target on Loxo shares to $170 from $130.
04/16/18
STFL
04/16/18
NO CHANGE
STFL
Buy
Blueprint data leaves 'door wide open' for Loxo's LOXO-292, says Stifel
Stifel analyst Stephen Willey noted that Blueprint Medicines (BPMC) reported data from the dose-escalation portion of its Phase 1 trial of BLU-667 at this weekend's AACR meeting. He believes BLU-667 looks like "a sufficiently viable asset for RET-altered tumors," but he also thinks the data has left the competitive window "wide-open" for Loxo Oncology (LOXO) ahead of preliminary LOXO-292 data expected at the ASCO meeting in June. Loxo's data now potentially could shift sentiment on what consensus has been presuming to be a $1B+ opportunity equally-shared between the two companies, Willey tells investors. He maintains a Buy rating on Loxo shares.
05/09/18
JMPS
05/09/18
NO CHANGE
Target $152
JMPS
Outperform
Loxo Oncology price target increased to $152 from $95 at JMP Securities
JMP Securities analyst Konstantinos Aprilakis raised his price target on Loxo Oncology to $152 from $95 following an update to his financial model after the company's Q1 earnings report, which he said highlighted its pipeline progress. He maintains an Outperform rating on Loxo shares.
JNCE Jounce Therapeutics
$11.96

-5.705 (-32.30%)

05/17/18
WELS
05/17/18
DOWNGRADE
Target $13
WELS
Market Perform
Wells Fargo downgrades Jounce on 'underwhelming' JTX2011 data
Wells Fargo analyst Jim Birchenough downgraded Jounce Therapeutics to Market Perform from Outperform and cut his price target for the shares to $13 from $37. The stock in premarket trading is down 31%, or $5.43, to $12.24. Overall response rates for JTX-2011 monotherapy in gastric cancer and in triple negative breast cancer, as well as for JTX-2011 plus Opdivo in gastric cancer and in triple negative breast cancer are "underwhelming" and "not competitive with other investigational drugs," Birchenough tells investors in a research note following review of the ASCO abstract. He advises taking a "wait and see approach to assess strength of aggregate data."
05/17/18
HCWC
05/17/18
NO CHANGE
Target $19
HCWC
Buy
Jounce Therapeutics price target lowered to $19 from $33 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Jounce Therapeutics to $19 citing the "limited activity on show" for JTX-2011, either as a monotherapy or when used in combination with Opdivo. With the stock already down today, "a reactionary downgrade here would make little sense," Chattopadhyay tells investors in a research note. He keeps a Buy rating on the shares.
05/17/18
05/17/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Molson Coors (TAP) downgraded to Hold from Buy at Stifel with analyst Mark Swartzberg saying he sees multiple expansion as unlikely because U.S. beer industry volume trends are getting worse, the company's U.S. share trends are not improving, and demographics favor continued pressure on per capita alcohol consumption. 2. Progressive (PGR) downgraded to Market Perform from Outperform at Keefe Bruyette with analyst Meyer Shields citing valuation. 3. CBS (CBS) downgraded to Neutral from Buy at BofA/Merrill with analyst Jessica Reif saying the lawsuit brought by CBS and the special committee alleging a breach of fiduciary duty by the National Amusements Inc. is a significant overhang for shares and will constrain outperformance until a ruling. 4. Canadian National (CNI) downgraded to Neutral on valuation at Macquarie with analyst Konark Gupta citing valuation. 5. Jounce Therapeutics (JNCE) downgraded to Market Perform from Outperform at Wells Fargo with analyst Jim Birchenough saying overall response rates for JTX-2011 monotherapy in gastric cancer and in triple negative breast cancer, as well as for JTX-2011 plus Opdivo in gastric cancer and in triple negative breast cancer are "underwhelming" and "not competitive with other investigational drugs." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/17/18
WELS
05/17/18
DOWNGRADE
WELS
Market Perform
Jounce Therapeutics downgraded to Market Perform from Outperform at Wells Fargo
BPMC Blueprint Medicines
$78.20

-7.92 (-9.20%)

04/16/18
JMPS
04/16/18
NO CHANGE
Target $109
JMPS
Outperform
Blueprint price target raised to $109 after BLU-667 data at JMP Securities
JMP Securities analyst Konstantinos Aprilakis raised his price target on Blueprint Medicines to $109 from $97 after the company presented data from the Phase I ARROW trial of BLU-667 in patients with solid tumors driven by alterations in RET at the American Association for Cancer Research annual meeting. Among all 53 enrolled patients, an "impressive" 41 patients remained on BLU-667 as of the data cutoff date, Aprilakis noted. He reiterates an Outperform rating on Blueprint shares.
NKTR Nektar
$77.14

-8.65 (-10.08%)

05/14/18
HCWC
05/14/18
NO CHANGE
Target $125
HCWC
Buy
Nektar pullbacks 'could get compelling,' says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay said ASCO abstracts featuring data from Nektar's ongoing PIVOT-02 study have potentially reset expectations, but he also noted that the actual podium presentation is likely to include an updated cut of data from up to late May. The analyst, who thinks pullbacks in Nektar Therapeutics shares "could get compelling," maintains a Buy rating and $125 price target on the stock.
05/17/18
JPMS
05/17/18
NO CHANGE
JPMS
Nektar may sell off modestly on ASCO abstract, says JPMorgan
JPMorgan analyst Jessica Fye says that consistent with her expectation heading into last night's abstracts, Nektar Therapeutics' NKTR-214 update was not definitive as it relates to the ultimate profile for the product. Management emphasized in advance that follow up would be limited for the new patients in the abstract, and this was "abundantly evident" with 22 of the 30 Phase II patients having had only one scan, Fye tells investors in a research note. Overall, the analyst sees "bright spots" in the abstract from signs of durable responses, tolerability, and an "intriguing" signal in bladder cancer. She notes, however, that some investors will pick at the decreased overall response rates in the new patients in melanoma, renal cell carcinoma and lung. While the limited follow up in the abstract was well-telegraphed, Nektar shares trading modestly lower today would not be surprising, Fye writes. The analyst keeps an Overweight rating on the stock.
05/16/18
PIPR
05/16/18
NO CHANGE
Target $125
PIPR
Overweight
Nektar 214+nivo response for melanoma not conclusive, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren keeps his Overweight rating and $125 price target on Nektar (NKTR) after the release of PIVOT ASCO abstract of NKTR 214+nivo (BMY). The analyst says that while the 1L melanoma response rate may be "slightly lower than some had hoped for", the 1L RCC response rate were "nicely above" what has been seen with ipi+nivo treatment. Van Buren adds that while small in numbers, "3/4 responses in 1L bladder and 1/3 responses in triple negative breast cancer are encouraging." The analyst believes that the stock may be down in the morning, but investors should not come to "rash conclusions", as the ASCO presentation with more patients and detail is likely to be positive.
05/11/18
PIPR
05/11/18
NO CHANGE
Target $125
PIPR
Overweight
Piper expects positive oral presentation from Nektar in early June
Piper Jaffray analyst Tyler Van Buren believes next Wednesday's ASCO abstract for Nektar's Phase I/II Pivot study of NKTR-214 in combination with nivolumab will be one of the most highly anticipated abstracts of the conference. The analyst notes, however, that the abstract will be from a February data cut while the oral presentation in early June will be from a data cut later this month. As such, the oral presentation will contain "significantly more mature data and should ultimately be relied on to make conclusions about the anti-tumor activity," Van Buren tells investors in a research note. He believes the oral presentation will be positive and keeps an Overweight rating on Nektar Therapeutics with a $125 price target following the company's Q1 results.
BMY Bristol-Myers
$52.54

0.32 (0.61%)

04/27/18
BMOC
04/27/18
UPGRADE
Target $47
BMOC
Market Perform
Bristol-Myers upgraded to Market Perform at BMO Capital on balanced risk/reward
As reported earlier, BMO Capital analyst Alex Arfaei upgraded Bristol-Myers to Market Perform from Underperform and kept his $47 price target. The analyst says that his concerns around the uncertainty of Opdivo sales erosion are mostly priced in, anticipating a 7% sales growth for the drug in 2019 and hoping for "more competitive" 1L-NSCLC readout that the recently disappointing IO data. Arfaei further states that the risk-reward around the stock price is now "more balanced".
04/27/18
04/27/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Facebook (FB) upgraded to Buy from Hold at Stifel with analyst Scott Devitt acknowledging that he was wrong to have stuck with his recent view on Facebook following its first earnings report. 2. Microsoft (MSFT) upgraded to Overweight from Neutral at JPMorgan with analyst Mark Murphy saying the global movement toward multi-cloud architectures will benefit Microsoft's Azure. 3. Bristol-Myers (BMY) upgraded to Market Perform from Underperform at BMO Capital with analyst Alex Arfaei saying his concerns around the uncertainty of Opdivo sales erosion are mostly priced in, anticipating a 7% sales growth for the drug in 2019 and hoping for "more competitive" 1L-NSCLC readout that the recently disappointing IO data. 4. Nike (NKE) upgraded to Buy from Hold at HSBC. 5. Intel (INTC) upgraded to Market Perform from Underperform at Bernstein with analyst Stacy Rasgon citing the company's "very strong" Q1 report. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/10/18
STFL
05/10/18
NO CHANGE
STFL
Hold
Exelixis pullback may create interesting entry point, says Stifel
After Exelixis (EXEL) and partner Roche (RHHBY) announced the Phase 3 IMblaze370 trial did not achieve statistical-significance on the primary efficacy endpoint evaluating the ability of a combination of a MEK inhibitor and anti-PD-L1 to improve overall survival in patients with microsatellite stable metastatic colorectal cancer, Stifel analyst Stephen Willey said he believes attrition in Exelixis shares might create an interesting entry point. The failure of IMblaze370 removes some of Exelixis' longer-term optionality and he expects topics of RCC growth/competition, label expansion, and longer-term cabozantinib exclusivity to remain core to the story going forward, said Willey who has a Hold rating on the stock. Array BioPharma (ARRY) also has Phase 1/2 development collaborations in place with both Bristol-Myers (BMY) and Merck (MRK) evaluating the MEK/PD-1 hypothesis in earlier-lines of MSS mCRC, noted Willey, who said he would "be opportunistic" on any weakness in its shares. He maintains a Buy rating on Array, which is down 5% in pre-market trading.

TODAY'S FREE FLY STORIES

CDTI

CDTi

$0.34

0.01 (3.08%)

18:15
09/21/18
09/21
18:15
09/21/18
18:15
Hot Stocks
CDTi sees September 21 as effective date of reverse stock split »

CDTi Advanced Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUK

Duke Energy

$79.82

-0.81 (-1.00%)

18:08
09/21/18
09/21
18:08
09/21/18
18:08
Hot Stocks
Duke Energy restored nearly 1.8M outages in NC, SC during past week »

Duke Energy crews today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 11

    Nov

JNJ

Johnson & Johnson

$142.85

0.85 (0.60%)

18:01
09/21/18
09/21
18:01
09/21/18
18:01
Hot Stocks
Johnson & Johnson's Janssen discloses phase 3 study results of Esketamine »

The Janssen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 28

    Oct

UAL

United Continental

$89.94

0.8 (0.90%)

17:39
09/21/18
09/21
17:39
09/21/18
17:39
Periodicals
United pilots refuse contract changes on regional routes, Reuters says »

United Airlines pilots…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

XLE

Energy Select Sector SPDR

$75.11

0.5132 (0.69%)

, XLU

Utilities SPDR

$53.04

0.2049 (0.39%)

17:36
09/21/18
09/21
17:36
09/21/18
17:36
General news
Week ending ETF Scorecard: Materials outperform, Utlilites slump »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$75.11

0.5132 (0.69%)

XLU

Utilities SPDR

$53.04

0.2049 (0.39%)

IYR

DJ US Real Estate Index Fund

$81.88

-0.06 (-0.07%)

XLP

Consumer Staples Sector SPDR

$55.02

0.1285 (0.23%)

XLY

Consumer Discretionary Sector SPDR

$116.98

-0.4288 (-0.37%)

XLB

S&P Select Materials SPDR

$60.54

-0.1312 (-0.22%)

XLF

Financial Select Sector

$28.73

-0.1175 (-0.41%)

XLV

Health Care Select Sector SPDR

$94.26

0.1571 (0.17%)

XLK

Technology Select Sector SPDR

$74.68

-0.2056 (-0.27%)

XLI

Industrial Select Sector SPDR

$79.71

0.2338 (0.29%)

GLD

SPDR Gold Trust

$113.48

-0.77 (-0.67%)

SLV

iShares Silver Trust

$13.44

-0.01 (-0.07%)

USO

United States Oil Fund

$14.95

0.145 (0.98%)

UNG

United States Natural Gas Fund

$24.60

0.235 (0.96%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$86.24

0.05 (0.06%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$114.72

0.04 (0.03%)

TLT

iShares 20+ Year Treasury Bond Fund

$117.12

-0.02 (-0.02%)

IEF

iShares 7-10 Year Treasury Bond ETF

$101.00

0.03 (0.03%)

SHY

iShares 1-3 Year Treasury Bond

$83.05

0.02 (0.02%)

IWD

iShares Russell 1000 Value

$129.51

0.13 (0.10%)

IWF

iShares Russell 1000 Growth

$155.30

-0.55 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OHGI

One Horizon Group

$0.18

-0.0088 (-4.63%)

17:34
09/21/18
09/21
17:34
09/21/18
17:34
Syndicate
Breaking Syndicate news story on One Horizon Group »

One Horizon Group files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTX

Cytori Therapeutics

$0.41

-0.033 (-7.38%)

17:31
09/21/18
09/21
17:31
09/21/18
17:31
Syndicate
Breaking Syndicate news story on Cytori Therapeutics »

Cytori Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEM

Newmont Mining

$31.56

0.05 (0.16%)

17:22
09/21/18
09/21
17:22
09/21/18
17:22
Syndicate
Breaking Syndicate news story on Newmont Mining »

Newmont Mining files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 25

    Oct

CB

Chubb

$139.87

-0.05 (-0.04%)

17:22
09/21/18
09/21
17:22
09/21/18
17:22
Hot Stocks
Chubb CEO Greenberg sells $8.6M in common stock »

Chubb CEO Evan Greenberg…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTVT

vTv Therapeutics

$0.80

0.0096 (1.21%)

17:21
09/21/18
09/21
17:21
09/21/18
17:21
Hot Stocks
vTv says FDA advised that azeliragon efficacy be shown in at least 2 trials »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VYGR

Voyager Therapeutics

$18.21

-0.27 (-1.46%)

17:17
09/21/18
09/21
17:17
09/21/18
17:17
Hot Stocks
Breaking Hot Stocks news story on Voyager Therapeutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNRC

Generac

$57.99

-0.02 (-0.03%)

17:16
09/21/18
09/21
17:16
09/21/18
17:16
Hot Stocks
Generac announces new $250M share repurchase program »

The company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

, IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

17:13
09/21/18
09/21
17:13
09/21/18
17:13
Conference/Events
Independent Bank to host special shareholder meeting »

Special Shareholder…

GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

HRS

Harris

$164.33

1.685 (1.04%)

17:13
09/21/18
09/21
17:13
09/21/18
17:13
Hot Stocks
Harris awarded $255.4M Department of Defense contract »

Harris Corp has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PMBC

Pacific Mercantile Bancorp

$9.25

-0.5 (-5.13%)

17:10
09/21/18
09/21
17:10
09/21/18
17:10
Hot Stocks
Breaking Hot Stocks news story on Pacific Mercantile Bancorp »

FJ Capital Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

WSC

WillScot

$17.10

-0.05 (-0.29%)

17:10
09/21/18
09/21
17:10
09/21/18
17:10
Syndicate
Breaking Syndicate news story on WillScot »

WillScot files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTEA

DAVIDsTEA

$2.50

-0.9 (-26.47%)

17:09
09/21/18
09/21
17:09
09/21/18
17:09
Hot Stocks
Breaking Hot Stocks news story on DAVIDsTEA »

TDM Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NYT

New York Times

$23.45

0.3 (1.30%)

, EXPE

Expedia

$133.73

-0.77 (-0.57%)

17:08
09/21/18
09/21
17:08
09/21/18
17:08
Hot Stocks
Expedia president Bhutani joins New York Times board »

The New York Times…

NYT

New York Times

$23.45

0.3 (1.30%)

EXPE

Expedia

$133.73

-0.77 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

, GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

17:08
09/21/18
09/21
17:08
09/21/18
17:08
Conference/Events
Guaranty Bancorp to host special shareholder meeting »

Special Shareholder…

IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

, ANDV

Andeavor

$154.80

2.19 (1.44%)

17:01
09/21/18
09/21
17:01
09/21/18
17:01
Conference/Events
Andeavor to host special shareholder meeting »

Special Shareholder…

MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

ANDV

Andeavor

$154.80

2.19 (1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Sep

ANDV

Andeavor

$154.80

2.19 (1.44%)

, MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

16:59
09/21/18
09/21
16:59
09/21/18
16:59
Conference/Events
Marathon Petroleum to host special shareholder meeting »

Special Shareholder…

ANDV

Andeavor

$154.80

2.19 (1.44%)

MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

EPRT

Essential Properties Realty Trust

$14.49

-0.015 (-0.10%)

16:45
09/21/18
09/21
16:45
09/21/18
16:45
Hot Stocks
Breaking Hot Stocks news story on Essential Properties Realty Trust »

Integrated Core…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBSI

Barrett Business

$63.67

0.04 (0.06%)

16:43
09/21/18
09/21
16:43
09/21/18
16:43
Hot Stocks
SEC says Barrett Business to pay $1.5M penalty over improper accounting »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIGA

Siga Technologies

$7.25

0.5 (7.41%)

16:42
09/21/18
09/21
16:42
09/21/18
16:42
Conference/Events
Siga Technologies to host business news update conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

SPY

SPDR S&P 500 ETF Trust

$292.03

-0.1774 (-0.06%)

, USO

United States Oil Fund

$14.95

0.145 (0.98%)

16:36
09/21/18
09/21
16:36
09/21/18
16:36
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 0.1K…

SPY

SPDR S&P 500 ETF Trust

$292.03

-0.1774 (-0.06%)

USO

United States Oil Fund

$14.95

0.145 (0.98%)

GLD

SPDR Gold Trust

$113.48

-0.77 (-0.67%)

FXE

Euro Currency Trust

$112.55

-0.27 (-0.24%)

FXC

CurrencyShares Canadian Dollar Trust

$76.37

-0.09 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.